Log in

Relevant bibliographies by topics / Refractory bullous pemphigoid

Contents

Journal articles

Academic literature on the topic 'Refractory bullous pemphigoid'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Refractory bullous pemphigoid.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Refractory bullous pemphigoid"

1

Pratasava, Valeryia, Vikram N. Sahni, Aishwarya Suresh, et al. "Bullous Pemphigoid and Other Pemphigoid Dermatoses." Medicina 57, no. 10 (2021): 1061. http://dx.doi.org/10.3390/medicina57101061.

Full text

Abstract:

The pemphigoid family of dermatoses is characterized by autoimmune subepidermal blistering. The classic paradigm for pemphigoid, and the most common member, is bullous pemphigoid. Its variable clinical presentation, with or without frank bullae, is linked by significant pruritus afflicting the elderly. Mucous membrane pemphigoid is an umbrella term for a group of subepidermal blistering dermatoses that favor the mucosal membranes and can scar. Epidermolysis bullosa acquisita is a chronic blistering disorder characterized by skin fragility, sensitivity to trauma, and its treatment-refractory na

APA, Harvard, Vancouver, ISO, and other styles

2

D'Agostino, Giovanni Marco, Giulio Rizzetto, Andrea Marani, et al. "Bullous Pemphygoid and Novel Therapeutic Approaches." Biomedicines 10, no. 11 (2022): 2844. http://dx.doi.org/10.3390/biomedicines10112844.

Full text

Abstract:

Bullous pemphigoid is a subepidermal blistering disease associated with autoantibodies (auto-ab) to BP180 and BP230 which affects elderly patients, predominately. Although it is a rare disease, bullous pemphigoid is the most common among the autoimmune bullous skin diseases. Systemic corticosteroids and immunosuppressants represent milestones in the treatment of patients suffering from bullous pemphigoid; however, therapeutic management of patients still represents a clinical challenge, owing to the chronic nature of the disease and to potential adverse effects related to the long-term use of

APA, Harvard, Vancouver, ISO, and other styles

3

Mereniuk, Eric, Laura Sabbah, and Jean-Paul Makhzoum. "A Case of Severe and Refractory Membranous Nephropathy Associated to Mucous Membrane Pemphigoid." Case Reports in Nephrology 2021 (May 11, 2021): 1–4. http://dx.doi.org/10.1155/2021/9940293.

Full text

Abstract:

Primary membranous nephropathy (MN) and mucous membrane pemphigoid (MMP) are two autoimmune conditions with well-defined diagnostic and treatment guidelines. MN has been linked to bullous pemphigoid (BP) in certain case reports, though little is known regarding the association of MN and other bullous diseases. The association of MN and MMP has rarely been described, and very little data exist regarding the treatment of this association. We report a case of severe refractory membranous nephropathy secondary to mucous membrane pemphigoid successfully treated with rituximab. A 35-year-old woman w

APA, Harvard, Vancouver, ISO, and other styles

4

Silva, Nuno, Andreia Costa, Fernando Salvador, and Elisa Serradeiro. "Penfigoide Bolhoso Tratado com Sucesso com Rituximab." Acta Médica Portuguesa 30, no. 3 (2017): 243. http://dx.doi.org/10.20344/amp.7812.

Full text

Abstract:

Bullous pemphigoid is an autoimmune disease characterized by subepidermal blister formation. Can be self-limiting but when necessary treatment includes the use of corticosteroids, immunosuppressants, and biological agents. We present the case of a 37 year old patient with a severe and refractory presentation of bullous pemphigoid. After about a month of treatment with various first line drugs and with no response, we chose to start rituximab and clear improvement of the lesions was observed. The authors aim to highlight the usefulness and effectiveness of this drug in this disease.

APA, Harvard, Vancouver, ISO, and other styles

5

Altmann, Stefanie, Dominique Jacobs, Thomas Brown, Preetha Kamath, and Karthik Krishnamurthy. "Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination." SKIN The Journal of Cutaneous Medicine 6, no. 3 (2022): 238–42. http://dx.doi.org/10.25251/skin.6.3.10.

Full text

Abstract:

As the SARS-CoV-2 vaccinated population increases, there have been many reports of vaccine-induced cutaneous reactions but scarce information on vaccine-induced autoimmune bullous disease. Vaccinations have been associated with the unmasking or development of autoimmune bullous disease; however, there is little data on SARS-CoV-2, specifically. We report a rare case of new-onset pemphigoid in a 70-year-old male following the second dose of the mRNA-1273 vaccine. The patient’s disease has been refractory to treatment, thus the underlying pathophysiology in vaccine-induced pemphigoid is likely u

APA, Harvard, Vancouver, ISO, and other styles

6

Uchida, Shusuke, Naoki Oiso, Hiroshi Koga, et al. "Refractory bullous pemphigoid leaving numerous milia during recovery." Journal of Dermatology 41, no. 11 (2014): 1003–5. http://dx.doi.org/10.1111/1346-8138.12650.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

JENKINS, R. E., S. A. VAUGHAN JONES, and M. M. BLACK. "Conversion of pemphigoid gestationis to bullous pemphigoid- two refractory cases highlighting this association." British Journal of Dermatology 135, no. 4 (1996): 595–98. http://dx.doi.org/10.1046/j.1365-2133.1996.d01-1047.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

JENKINS, R. E., S. A. VAUGHAN JONES, and M. M. BLACK. "Conversion of pemphigoid gestationis to bullous pemphigoid— two refractory cases highlighting this association." British Journal of Dermatology 135, no. 4 (1996): 595–98. http://dx.doi.org/10.1111/j.1365-2133.1996.tb03838.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Thomsen, Kenneth, Mette Deleuran, Christian Vestergaard, Mette Holm, Rikke Riber-Hansen, and Rikke Bech. "Severe Infantile Bullous Pemphigoid Treated with Dapsone after Bridging with Systemic Glucocorticoid." Case Reports in Dermatology 11, no. 2 (2019): 187–93. http://dx.doi.org/10.1159/000501359.

Full text

Abstract:

We present a case of severe and treatment-refractory bullous pemphigoid in a 3-month-old child. After topical and systemic corticoid treatment proved inefficient, dapsone 0.75 mg/kg was added initially without success. Disease control was reached with dapsone 1.5 mg/kg in addition to both topical and systemic glucocorticoid treatment, leaving the child with several side effects of the glucocorticoid treatment.

APA, Harvard, Vancouver, ISO, and other styles

10

Bishnoi, Anuradha, Dipankar De, Sanjeev Handa, and Rahul Mahajan. "Biologics in autoimmune bullous diseases: Current scenario." Indian Journal of Dermatology, Venereology and Leprology 87 (July 1, 2021): 611–20. http://dx.doi.org/10.25259/ijdvl_886_19.

Full text

Abstract:

Autoimmune bullous diseases can be intraepidermal (pemphigus group of disorders) or subepidermal (pemphigoid group of disorders). The treatment of these disorders chiefly comprises corticosteroids and immunosuppressant adjuvants like azathioprine and mycophenolate mofetil. Autoantibodies are the main mediators of these diseases. Rituximab, a chimeric anti-CD20 monoclonal antibody targeting B-cells, has emerged as an excellent treatment option for refractory pemphigus vulgaris in the last decade. Since then, many new biologics have been proposed/explored for managing autoimmune bullous diseases

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!